Skip to main content
Premium Trial:

Request an Annual Quote

Clearbridge Gains FDA Registration for ClearCell FX1 System

NEW YORK (GenomeWeb) – Clearbridge BioMedics said today that it has registered its target cell enrichment device, the ClearCell FX1 system, as a Class I medical device with the US Food and Drug Administration.

ClearCell is a label-free, microfluidics-based liquid biopsy device that allows for the enrichment of target cells from blood. The system had previously been CE-marked for in vitro diagnostic use in Europe, and was available in China as a China FDA-approved device. It was commercially launched in 2015.

According to Clearbridge CEO Michael Paumen, the company hopes that achieving registration of the device with the FDA will help accelerate liquid biopsy research and diagnostics development using the platform.

"We will continue to work with our partners and the authorities to further validate the system, for use in cancer diagnostics, personalized therapy management, and patient monitoring,” he said in a statement.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.